Startups

Axonis Therapeutics logo

Axonis Therapeutics

axonis.us

Develops oral small-molecule medicines that enhance KCC2, a neuronal chloride transporter essential for inhibitory signaling in the brain. Its lead investigational drug, AXN-027, is in clinical development for epilepsy and pain. The company’s discovery platform also supports medicines for other neurological, psychiatric and neurodevelopmental disorders.

Team

Bob YantBoard Observer
Brock ReeveBoard Director
Clifford WoolfScientific Advisor, Pain
Corey GoodmanExecutive Chairman and Co-Founder and Scientific Advisor
Doug GiordanoBoard Observer
Jacqueline FrenchScientific Advisor, Clinical Epilepsy
James GuestScientific Advisor, Clinical Spinal Cord Injury
Jeff ImbaroCOO
Joanna StanickaChief Executive Officer, President and Co-Founder and Board Director
Jonathan LeffBoard Director
Lisa McKerracherScientific Advisor and Co-Founder
Marcelo BigalChief Medical Advisor and Board Observer
Olga DanilchankaBoard Observer
Raymond J. KelleherBoard Director
Roger PorterScientific Advisor, Epilepsy and Clinical Pharmacology
Shane V. HegartyCSO and Co-founder
Wolfgang LiedtkeScientific Advisor, KCC2 Neurobiology and Pain
Yves De KoninckChair of Scientific Advisory Board
Zhigang HeScientific Advisor, KCC2 Neurobiology and Neurotrauma

Investments